Top gene therapy regulator forced out at FDA

Top gene therapy regulator forced out at FDA

She had worked closely with former CBER head Peter Marks on establishing new paths for bringing gene therapies to market, particularly in rare diseases.

FDA cell and gene therapy director exit increases ‘volatility’ for sector - Pharmaceutical Technology

Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week.

FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes

The FDA's top leadership in its cell and gene therapy division have been let go, sources told Endpoints News, in the latest shakeup at the agency that has seen significant numbers of staff and other ...